Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11351 - 11375 of 11783 in total
Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.[A225691, A225696] This drug is used in the treatment of thrombocytopenia.
Investigational
Matched Description: … Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary …
RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.
Investigational
Matched Description: … RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. …
Idronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.
Investigational
Matched Description: … Idronoxil is a substance that is being studied in the treatment of cancer. …
ETC-588, or LUV (large unilamellar vesicles), is made of naturally occurring lipids that circulate through arteries to facilitate the role of high-density lipoprotein (HDL) in removing accumulated cholesterol and other lipids from cells including those in the arterial wall. LUV are capable of transporting excess cholesterol from the vasculature to...
Investigational
Matched Description: … Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. …
25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It was discovered in 2014 at the University of Copenhagen.
Experimental
Matched Description: … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective …
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
Investigational
Matched Description: … Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial …
PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).
Investigational
Matched Description: … PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy …
CDX-6512 is a modified, gastrointestinal-stable bacterial leucine decarboxylase. Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.[L46651, L46656]
Investigational
Matched Description: … CDX-6512 is a modified, gastrointestinal-stable bacterial leucine decarboxylase. …
Benapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (Cuti) or Acute Pyelonephritis (AP)).
Investigational
Matched Description: … Benapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety …
Forimtamig is under investigation in clinical trial NCT06055075 (A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma).
Investigational
Matched Description: … Forimtamig is under investigation in clinical trial NCT06055075 (A Study Evaluating Safety, Tolerability …
Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
Investigational
Matched Description: … Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive …
CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Experimental
Matched Description: … CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in …
Delpazolid (LCB01-0371) is under investigation in clinical trial NCT01554995 (A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study).
Investigational
Matched Description: … Delpazolid (LCB01-0371) is under investigation in clinical trial NCT01554995 (A Clinical Study, Randomized …
Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase .
Experimental
Matched Description: … Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- …
2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).
Investigational
Matched Description: … 2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients …
Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).
Investigational
Matched Description: … Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular …
Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.
Investigational
Matched Description: … Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds …
Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis).
Investigational
Matched Description: … Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution …
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.
Investigational
Matched Description: … SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a
Centanafadine is under investigation in clinical trial NCT02827513 (A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects).
Investigational
Matched Description: … Centanafadine is under investigation in clinical trial NCT02827513 (A Phase 1 Study to Investigate the …
NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Investigational
Matched Description: … NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase …
LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Investigational
Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects....
Investigational
Matched Description: … Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green ... A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing. …
MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
Investigational
Matched Description: … MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by …
Displaying drugs 11351 - 11375 of 11783 in total